• Provider Login
  • Payors
  • Manufacturers
  • Blog
  • Careers
Avella Specialty Pharmacy
  • Locations
    • Retail Pharmacies
    • Mail-Order Facilities
      • Corporate Headquarters
      • National Distribution Center
      • 503A Compounding Facilities
  • Specialties
    • Addiction Management
    • Cardiovascular Disease
    • Dermatology
    • Fertility
    • Gastroenterology
    • Hepatitis
    • HIV / AIDS
    • Infusion Therapy
    • IG Therapy
    • Multiple Sclerosis
    • Oncology
    • Ophthalmology
    • Rheumatology
    • RSV
    • Transplant
    • Urology
  • Patients
    • FAQ
    • Patient Resources
  • Providers
    • Provider Portal
    • Specialties
  • Hospitals
    • 340B Program
    • 503A Oncology
  • Services
    • Adherence
    • Education
    • Financial Assistance
    • FundFinder
    • Digital Calling Card
    • Limited Distribution Drugs
    • Portal Technology
    • Prior Authorization
    • Privacy
  • About
    • Accreditations
    • Residency Program
    • Careers
    • News
    • Contact
Menu
  • Locations
    • Retail Pharmacies
    • Mail-Order Facilities
      • Corporate Headquarters
      • National Distribution Center
      • 503A Compounding Facilities
  • Specialties
    • Addiction Management
    • Cardiovascular Disease
    • Dermatology
    • Fertility
    • Gastroenterology
    • Hepatitis
    • HIV / AIDS
    • Infusion Therapy
    • IG Therapy
    • Multiple Sclerosis
    • Oncology
    • Ophthalmology
    • Rheumatology
    • RSV
    • Transplant
    • Urology
  • Patients
    • FAQ
    • Patient Resources
  • Providers
    • Provider Portal
    • Specialties
  • Hospitals
    • 340B Program
    • 503A Oncology
  • Services
    • Adherence
    • Education
    • Financial Assistance
    • FundFinder
    • Digital Calling Card
    • Limited Distribution Drugs
    • Portal Technology
    • Prior Authorization
    • Privacy
  • About
    • Accreditations
    • Residency Program
    • Careers
    • News
    • Contact

Specialty Pharmacy Insights

Return to blog

3 Ways the New IMBRUVICA® Formulation Will Have a Big Impact on Patients

Posted by Avella Specialty Pharmacy on Fri, Mar 23, 2018
  • Tweet

Imbruvica Blister Pack Group In the time since IMBRUVICA® (ibrutinib) was first approved by the FDA in 2013 it has undergone many changes. This includes multiple indication expansions to various types of leukemia and lymphoma, approval as a first-line therapy, and even exploration into use in combination with other cancer treatment therapies. 

Recently, it was announced that IMBRUVICA would be undergoing a formulation change. Now, rather than 140mg capsules, IMBRUVICA will be a single pill, taken once daily. 

While this change seems small, it is hugely beneficial to patients for a few reasons: 

  1.  Imbruvica 4 PillsOne pill. IMBRUVICA patients will now only take one pill per day. This makes it much easier for a patient to remember to take their medication as prescribed, and will help keep patients on track with their therapy, which helps the medication work its best.  
  2.  Easier packaging. IMBRUVICA now comes in a blister pack, rather than a pill bottle. This new pack has spaces where patients can take notes, and track day-by-day where they are in their therapy regimen. This also makes it very clear if a day was missed. Additionally, the packaging includes 4 weeks worth of medication (28 days) and even contains a refill reminder on day 21.

    Imbruvica Blister Pack Open 
  3. Easier to swallow. Tablets are the same size or smaller than the capsules. 

For healthcare providers prescribing IMBRUVICA, it's important to note a few things:

  • New IMBRUVICA tablets are now available from Avella
  • IMBRUVICA 140mg capsules will be discontinued after May 15, 2018
  • Tablets contain the same active ingredient as the capsules, so there is no change to the dosing
  • Changing from IMBRUVICA capsules to tablets is not an automatic change. Every patient will require a new prescription featuring the updated NDCs

If you are a patient taking IMBRUVICA, be sure to reach out to your physician about an updated prescription. You can also watch this educational video about the change. 

If you are a healthcare provider, you can get started by downloading the new Avella Imbruvica referral form, or reaching out to your Avella account manager to get started. 

Get the New Rx Form

Connect with Account Manager

Topics Oncology Cancer limited distribution drugs

CONNECT WITH US

  • social-twitter
  • social-linkedin
  • social-youtube
  • social-facebook
  • social-yelp

Subscribe For Updates

Recent Posts

Posts by Topic

  • Avella (28)
  • Oncology (23)
  • Specialty Pharmacy (18)
  • Hepatitis (14)
  • Adherence (12)
  • HIV/AIDS (6)
  • Medication (6)
  • Cancer (5)
  • Fertility (5)
  • limited distribution drugs (4)
  • Accreditations (3)
  • Patients (3)
  • Public Health (3)
  • Addiction Management (2)
  • Pain Management (2)
  • mobile health (2)
  • 340b Program (1)
  • Complex Disease (1)
  • Dermatology (1)
  • IG Therapy (1)
  • In the News (1)
  • Inc (1)
  • Inc 5000 (1)
  • Industry News (1)
  • Infusion Therapy (1)
  • LLS (1)
  • Managed Care (1)
  • Partners (1)
  • Pharmacist (1)
  • Psoriasis (1)
  • RSV (1)
  • Rheumatoid Arthritis (1)
  • outsourcing facility (1)
  • payers (1)
see all
  • specialty_accreditation_seal-1
  • rsz_mail_service_accreditationseal
  • Addiction Management
  • Cardiovascular Disease
  • Dermatology
  • Fertility
  • Gastroenterology
  • Hepatitis
  • HIV / AIDS
  • Infusion Therapy
  • IG Therapy
  • Multiple Sclerosis
  • Oncology
  • Ophthalmology
  • Rheumatology
  • RSV
  • Transplant
  • Urology
  • Contact Avella
  • Terms of Use
  • Privacy
  • Blog
  • 877-546-5779
© 2025 Avella Specialty Pharmacy
  • Twitter
  • LinkedIn
  • YouTube
  • Facebook
.